Journal of Cancer Genetics And Biomarkers

Journal of Cancer Genetics And Biomarkers

Journal of Cancer Genetics And Biomarkers – Aim And Scope

Open Access & Peer-Reviewed

Submit Manuscript

Journal of Cancer Genetics and Biomarkers

Publishing rigorous molecular and computational studies in cancer genetics and biomarker validation.

Mission & Vision

The Journal of Cancer Genetics and Biomarkers (JCGB) publishes high-quality research that advances understanding of cancer genomics, biomarker discovery, and their translation into clinical practice. We emphasize methodological rigor, reproducibility, and ethical stewardship of genomic data. Our vision is to accelerate precision oncology by disseminating science that directly informs diagnosis, prognosis, and therapy.

70+Research domains actively represented in JCGB
82%Articles sharing datasets or code for reproducibility
45%Submissions involving novel biomarker validation strategies
5 continentsEditorial board coverage for contextual peer review
Core Research Areas

Cancer Genomics

Germline predisposition, somatic mutation landscapes, chromothripsis, mutational signatures, DNA repair deficiencies, and chromatin remodeling.

Biomarker Discovery & Validation

Multi-tier validation from in silico discovery through analytical and clinical validation, including ctDNA, cfRNA, exosomes, and metabolic signatures.

Tumor Microenvironment

Immune cell infiltration, cytokine networks, microbiome interactions, stromal remodeling, angiogenesis, and metabolic competition.

Multi-Omic Integration

Systems approaches integrating genomics, transcriptomics, proteomics, metabolomics, and radiomics to generate comprehensive tumor atlases.

Liquid Biopsy

Non-invasive diagnostics including circulating tumor cells, cell-free DNA/RNA, exosomes, and metabolite-based assays.

Precision Therapeutics

Linking genomic alterations to therapy selection, resistance mechanisms, and adaptive trial designs.

Computational & AI Methods
Machine Learning & AI in Oncology

JCGB welcomes computational innovations that drive discovery at scale. We prioritize machine learning algorithms, predictive models, and decision-support tools that integrate genomics, proteomics, pathology, imaging, and electronic health records. Manuscripts must demonstrate interpretability, clinical relevance, and adherence to data governance best practices.

Data Science & Informatics

Research in data harmonization, federated learning, privacy-preserving analytics, and bioinformatics pipelines that enable reproducible cancer genomics research. We encourage submissions discussing bias mitigation and sustainable data stewardship frameworks.

Translational, Clinical & Policy Domains
Clinical Implementation

JCGB publishes pragmatic clinical trials, real-world evidence studies, implementation science, and decision-analysis models that highlight barriers and enablers to biomarker adoption. Topics include reimbursement pathways, laboratory accreditation, and electronic decision support.

Ethics, Equity & Policy

We seek frameworks for informed consent, data sovereignty, community engagement, and culturally competent genomic counseling. Manuscripts addressing algorithmic bias, sustainable biobanking, cross-border data transfer, and benefit sharing with underrepresented communities are encouraged.

Not Considered

JCGB is not the ideal venue for manuscripts that:

  • Focus exclusively on preclinical drug screening without genomic or biomarker context.
  • Lack novel insight into cancer-specific mechanisms or biomarker performance.
  • Do not provide adequate statistical power, validation, or reproducibility evidence.
  • Report purely descriptive case studies lacking molecular analysis or translational inference.
  • Apply standard machine learning / AI to small datasets without significant methodological novelty.
  • Are primarily epidemiological or lack molecular/genomic/biomarker analysis.
Article Types

Original Research

Comprehensive studies presenting new experimental data, computational discoveries, or translational insights supported by robust methodology and validation.

Rapid Communications

High-impact findings requiring swift dissemination—such as emergent resistance mechanisms, novel biomarkers, or urgent public health relevance—presented concisely with strong evidence.

Reviews & Meta-Analyses

State-of-the-art syntheses that map progress, identify gaps, and chart future directions in specific domains (e.g., organ-specific biomarker strategies, AI in pathology).

Methods & Protocols

Detailed experimental or computational methods, benchmarking studies, and protocol standardisations that enable reproducible research and clinical translation.

Clinical Case Series

Carefully documented cases illustrating biomarker-driven decision-making, therapy adaptation, or novel diagnostic use in real-world oncology practice.

Policy & Perspective Pieces

Thought leadership addressing policy shifts, regulatory landscapes, ethical dilemmas, equity considerations, and cross-sector collaboration models.

Metrics & Submission Standards

JCGB emphasizes methodological rigor, reproducibility, and ethical stewardship. Before submission, confirm:

  • Your manuscript directly addresses at least one JCGB scope domain with explicit mention in the abstract and keywords.
  • Experimental design includes validation strategies (technical replicates, orthogonal methods, independent cohorts, or computational benchmarks).
  • You have documented ethical approvals, consent procedures, and data management plans.
  • Figures, tables, and supplemental files provide full transparency for reanalysis.
  • Your discussion articulates translational relevance, implementation considerations, or policy implications.
92%Internal data indicate that 92 % of JCGB articles receive clinician downloads within 72 hours of publication.
35%Approximately 35 % of submitted manuscripts include a patient advocacy partner (co-investigator, collaborator, or advisor).
18%Articles cited in regulatory or clinical guidelines within two years
Key Focus Terms

JCGB emphasizes the following core areas. Authors are encouraged to align submissions with these domains:

  • Cancer genomics
  • Somatic mutation landscapes
  • Germline predisposition
  • Clonal evolution
  • Epigenetic reprogramming
  • Single-cell sequencing
  • Spatial transcriptomics
  • Liquid biopsy
  • Circulating tumor DNA
  • Minimal residual disease
  • Tumor immune microenvironment
  • Neoantigen prediction
  • Checkpoint inhibition
  • CAR-T therapy biomarkers
  • Precision radiomics
  • Digital pathology
  • Machine learning oncology
  • Explainable AI
  • Multi-omics integration
  • Proteomic signatures
  • Metabolomic profiling
  • Exosomal biomarkers
  • Tumor heterogeneity
  • Adaptive clinical trials
  • Synthetic lethality
  • Drug resistance mechanisms
  • Pharmacogenomics
  • Real-world evidence
  • Health technology assessment
  • Genomic data ethics
  • Indigenous genomic data
  • Biobanking governance
  • AI fairness
  • Population genomics
  • Cancer disparities
  • Implementation science
  • Precision public health
  • CRISPR screening
  • Functional genomics
  • Radiogenomics
  • Bioinformatics pipelines
  • Data harmonisation
  • Federated learning
  • Privacy-preserving analytics
  • Electronic health records
  • Clinical decision support
  • Patient-reported outcomes
  • Cost-effectiveness
  • Regulatory science
  • Reimbursement models
  • Biomarker qualification
  • Diagnostic stewardship
  • Oncology informatics
  • AI governance
  • Equitable precision medicine
  • Cancer survivorship biomarkers
  • Systems oncology
  • Metabolic competition
  • Immune evasion
  • Translational biomarker research
Special Issues & Thematic Collections

JCGB welcomes proposals that align with the scope domains described above. Special issues should demonstrate clear objectives, timeliness, expert guest editors, and a recruitment plan that fosters diversity in geography, gender, and career stage. Visit the Proposing a Special Issue page for guidance on structuring proposals, timelines, and APC considerations.

Align Your Research with JCGB

Ready to contribute to a journal dedicated to the frontiers of cancer genetics and biomarker science? Review the author guidelines, refine your keywords, and submit today.

Scope queries: Share your abstract with [email protected] to receive editorial guidance on suitability. We respond within two business days with feedback or recommendations for alternative Open Access Pub titles if required.

Last updated: September 2025. JCGB revisits its scope annually to ensure alignment with emerging scientific discoveries, technological advances, and community needs. Scope revisions are guided by editorial board feedback and community input to maintain alignment with advances in cancer genomics / biomarker research.